Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.

导出 OA

翻译打印收藏纠错

作者： Adnan,Alsumali ^[1] ; Dominik,Lautsch ^[2] ; Rongzhe,Liu ^[3] ; Dipen,Patel ^[3] ; Sakina,Nanji ^[3] ; Laurence M,Djatche ^[2]

作者单位： Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA. adnan.alsumali@merck.com. ^[1] Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA. ^[2] Pharmerit - an OPEN Health Company, Bethesda, MD, USA. ^[3]

关键词 Budget impact Cost analysis Heart failure with reduced ejection fraction Vericiguat Worsening heart failure

主题词心力衰竭(Heart Failure);杂环化合物, 2环(Heterocyclic Compounds, 2-Ring);人类(Humans);嘧啶类(Pyrimidines);每搏输出量(Stroke Volume)

DOI 10.1007/s12325-021-01681-2

PMID 33860924

发布时间 2021-06-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交